Compare Amphastar Pharmaceuticals Inc (AMPH) vs NIO Inc. (NIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs NIO Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while NIO Inc. trades at $4.9 (market cap $12.35B). The key difference: NIO Inc. is far larger — about 15× Amphastar Pharmaceuticals Inc's market cap, and NIO Inc. is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | NIO | |
|---|---|---|
Market Cap | $826.08M | $12.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $7.89 |
52-Week Low | $16.87 | $3.90 |
Enterprise Value | $1.22B | $11.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
NIO trades at $4.78, unchanged on the day, with a bearish technical signal from moving averages. Revenue grew to $87.49B in 2025, but net losses persist at -$15.57B, though margins improved. Vehicle deliveries surged 62.9% year-over-year in June 2026, driven by strong ES9 performance. Cash flow remains negative, with a net cash outflow of -$10.87B in 2024.
The outlook is mixed: robust delivery growth and narrowing losses signal operational progress, but persistent cash burn and high debt pose risks. Analyst consensus leans bullish with 50% buy ratings, yet the stock faces headwinds from competitive pressures and macroeconomic concerns affecting Chinese EV stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
